Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
MTNB vs DARE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
MTNB Captures Overall Composite Edge (54.6 HOLD vs 43.1 HOLD), While DARE Leads 3–1 on Growth & Valuation Pillars
MTNB Overall Winner
6-Pillar Tally: MTNB 1 – 3 DARE (2 Tie)
Matrix Metrics: MTNB 4 – 4 DARE
As of Nov 19, 2026, Matinas BioPharma Holdings, Inc. (MTNB) captures the overall head-to-head institutional edge over Dare Bioscience, Inc. (DARE) on higher Unified Composite conviction (54.6/100 HOLD vs. 43.1/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality), while DARE wins 3–1 across the 6-pillar growth and valuation breakdown. MTNB trades at $0.81 (N/M Forward P/E, 0.0% operating margin) versus DARE at $0.45 (1.3x Forward P/E, -746.1% operating margin).
- Growth vs. Quality Trade-Off: MTNB earns the overall head-to-head edge with a stronger Unified Composite Score (54.6/100 HOLD vs. DARE 43.1/100 HOLD) and -7.20β · 147% Vol risk profile, whereas DARE leads top-line expansion (+2005.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0); meanwhile DARE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MTNB vs DARE
MTNB
Head-to-Head Winner
Matinas BioPharma Holdings, Inc.
$0.81
-10.98% 1D
Market Cap
$979,904
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
-7.20β · 147% Vol
Unified Composite Score
54.6
HOLD
Tech 53.0
Fund 58.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
DARE
Dare Bioscience, Inc. Common Stock
$0.45
+0.44% 1D
Market Cap
$8.8M
TTM Revenue
$1.4M
Forward P/E
1.3x
Beta / 30D Vol
1.52β · 112% Vol
Unified Composite Score
43.1
HOLD
Tech 35.0
Fund 46.0
Flow 50.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (MTNB 1 – 3 DARE)
1. Valuation Multiples
DARE
Forward P/E
N/M
1.3x
Trailing P/E
N/M
1.3x
PEG Ratio
N/M
N/M
EV / Revenue
N/M
N/M
2. Growth & Scale
DARE
Revenue Growth (YoY)
-100.0%
+2005.6%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$1.4M
Market Cap
$979,904
$8.8M
3. Profitability & Quality
MTNB
Gross Margin
N/A
N/A
Operating Margin
0.0%
-746.1%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-147.5%
-407.1%
4. Balance Sheet & Cash Flow
DARE
Cash Generation (TTM)
N/A
-$12M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$1.2M Net Cash
$12M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MTNB (4) vs DARE (4)| Institutional Metric | MTNB | DARE | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $979,904 | $8.8M | Tie | |
| Trailing P/E Ratio | N/M | 1.3x | DARE | |
| Forward P/E Ratio | N/M | 1.3x | DARE | |
| Revenue Growth (YoY) | -100.0% | +2005.6% | DARE | |
| Operating Margin (TTM) | 0.0% | -746.1% | MTNB | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -147.5% | -407.1% | MTNB | |
| 52-Week Range Position | 22% ($0–$3) | 1% ($0–$4) | MTNB | |
| Beta / 30D Volatility | -7.20β · 147% Vol | 1.52β · 112% Vol | DARE | |
| Unified Institutional Score | 54.6 / 100 (HOLD) | 43.1 / 100 (HOLD) | MTNB | |
| Trailing 12M Revenue (USD) | N/A | $1.4M | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | N/A ($1.2M Net Cash) | -$12M ($12M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
DARE +12.4 pp
3M Horizon
MTNB +352.36 pp
6M Horizon
MTNB +102.17 pp
1Y Horizon
MTNB +43.26 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MTNB Revenue | DARE Revenue | MTNB Op. Margin | DARE Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -12230.9% | N/A | MTNB |
| FY2019 | $0M | N/A | -21067.4% | N/A | MTNB |
| FY2020 | $0M | N/A | -15288.4% | N/A | MTNB |
| FY2021 | $0M | N/A | -74954.5% | N/A | MTNB |
| FY2022 | $0M | $10M | -771.3% | -313.9% | DARE |
| FY2023 | $0M | $0M | -2168.4% | -1101.9% | DARE |
| FY2024 | N/A | $0M | N/A | -239692.2% | DARE |
| FY2025 | N/A | $0M | N/A | -1315.5% | DARE |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MTNB
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact MTNB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
DARE
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact DARE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MTNB Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
DARE Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ MTNB vs DARE Key Questions & Quantitative Answers
As of Nov 19, 2026, Matinas BioPharma Holdings, Inc. (MTNB) captures the overall head-to-head institutional edge over Dare Bioscience, Inc. (DARE) on higher Unified Composite conviction (54.6/100 HOLD vs. 43.1/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality), while DARE wins 3–1 across the 6-pillar growth and valuation breakdown. MTNB trades at $0.81 (N/M Forward P/E, 0.0% operating margin) versus DARE at $0.45 (1.3x Forward P/E, -746.1% operating margin). Growth vs. Quality Trade-Off: MTNB earns the overall head-to-head edge with a stronger Unified Composite Score (54.6/100 HOLD vs. DARE 43.1/100 HOLD) and -7.20β · 147% Vol risk profile, whereas DARE leads top-line expansion (+2005.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0); meanwhile DARE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DARE leads the Growth & Scale pillar: MTNB posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DARE at +2005.6% YoY revenue growth and +0.0% YoY earnings growth on $1.4M TTM revenue (N/A gross margin, -746.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MTNB cumulative revenue shifted N/A while DARE shifted N/A. In operating R&D and SG&A reinvestment, MTNB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DARE.
DARE screens cheaper on headline valuation multiples. MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas DARE trades at 1.3x Forward P/E, 1.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MTNB (-147.5% ROE) versus DARE (-407.1% ROE) capital efficiency.
In options market volatility and institutional positioning, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.20β · 147% Vol realized risk). By comparison, DARE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 112% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
DARE vs MTNB · Reverse Pair
MTNB vs VTVT
· Sector Peer
DARE vs VTVT
· Sector Peer
DARE vs NDRA
· Sector Peer
DARE vs ACHV
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma